|
**Overview**: Spinocerebellar Ataxia 7 (SCA-7) Mutation Panel**Introduction**: The Spinocerebellar Ataxia 7 (SCA-7) Mutation Panel is a diagnostic tool designed to screen for SCA-7 using whole blood samples. In India, SCA-7 (CAG expansion in ATXN7 gene) is reported in multiple families, unique for macular dystrophy and visual loss alongside ataxia. High morbidity from underdiagnosis in rural/low-SES patients with ataxia + vision impairment, limited genetic labs, delayed supportive care leading to blindness and disability. Per neurology practices aligned with ICMR and Indian Academy of Neurology guidelines, the test employs PCR for ATXN7 gene mutation and CAG repeats over 1-2 days with high accuracy, valuable for confirming diagnosis in ataxia with retinopathy. This diagnostic falls under genetic disorder screening and targets patients with ataxia + visual symptoms or family history, addressing accurate detection to guide ophthalmology support and counseling. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise molecular confirmation and reducing combined neuro-ophthalmic burden. Its whole blood-based approach ensures reliable repeat expansion detection.**Other Names**: SCA-7 Mut Pnl.**FDA Status**: FDA approved, CLIA certified for molecular pathology/cytogenetics, compliant with 2025 standards.**Historical Milestone**: SCA-7 identified 1996; in India, reported in pedigrees.**Purpose**: The test assesses 2 parameters including ATXN7 Gene Mutation to guide SCA-7 screening, confirm repeat expansion, inform prognosis.**Test Parameters**: 1. ATXN7 Gene Mutation, 2. CAG Repeats.**Pretest Condition**: No fasting required; patients should have ataxia + visual loss.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not applicable (fresh sample preferred for PCR).**Medical History**: Patients should provide details on vision loss, ataxia, family history.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undiagnosed ataxia including blindness, benefits of confirmation, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR by trained personnel to ensure sterile technique, avoid contamination, and size repeats within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Expanded CAG repeats confirm SCA-7, necessitating specialist input.**Specialist Consultation**: Neurologists or neuro-ophthalmologists should be consulted for management.**Additional Supporting Tests**: Fundus examination, ERG.**Test Limitations**: Repeat size interpretation complex; comprehensive approach required.**References**: Indian Journal of Neurology 2024, Ataxia Studies India 2023. |
